An anti-ER “Riptac” enters phase 1.
ApexOnco Front Page
Recent articles
Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
Randomised data will be needed to answer lingering questions about DKN-01.
Both BCMA-targeting Car-T therapies will face US advisory committee scrutiny after all.
New listings reveal expanded phase 3 programmes for J&J’s Talvey and Amgen’s tarlatamab.
Opdivo plus Yervoy scores a remarkable survival benefit in Checkmate-8HW, whose control arm presents some comparability difficulties.
The first-line liver cancer Emerald-1 trial is positive, but only up to a point.
Skyscraper-08 yields a positive result that – with caveats – looks decent on a cross-trial basis too.